An Expanded Access Trial for Cancer Patients with Specific Mutations
An investigational drug is being used in an expanded access trial for advanced pancreatic and other cancer patients with specific genetic changes.
An Interview with Dr. Tyler Jacks
Dr. Tyler Jacks is one of the leading pancreatic cancer researchers. Read what he has to say about KRAS, organoids, and running a lab in a pandemic.
AACR Virtual Special Conference on Pancreatic Cancer: Day One Highlights
Let's Win and the Lustgarten Foundation present highlights of Day One of the AACR Virtual Special Conference on Pancreatic Cancer.
High-Dose Vitamin C Targeting KRAS and BRAF in Pancreatic Cancer
Dr. Manish Shah leads a clinical trial of high-dose vitamin C targeting KRAS and BRAF mutations in solid-tumor cancers, including pancreatic cancer.
Targeting Mutant KRAS with Immunotherapy
Dr. Beatriz Carreno explains how her team is targeting the KRAS mutation with a pancreatic cancer vaccine to make the immune system work against cancer.
Challenge Grant Recipients Moving Forward
The Pancreatic Cancer Collective awarded four teams a second round of New Therapies Challenge Grants, to further develop new pancreatic cancer treatment.
Dousing Out-of-Control KRAS Signaling in Pancreatic Cancer
Rene Bernards and his team are targeting the signaling pathway of the KRAS mutation, which occurs in almost all pancreatic cancers.
AACR Highlights: Sunday, September 8
Read the highlights of Sunday's sessions about early-stage clinical trials, oncogenes, and early detection at the AACR pancreatic cancer conference.
Immunotherapy to Attack a Common Pancreatic Cancer Mutation
Researchers are testing a type of immunotherapy to attack a variant of the KRAS mutation; KRAS mutations occur in almost all pancreatic cancers.
Combination Delivers a Dual Punch to Pancreatic Cell Growth
Dr. Conan Kinsey outlines a clinical trial that has moved quickly from the lab to phase I, with a dual approach to delivering pancreatic cancer treatment.